WE HELP YOU KEEP YOUR FEET
VOTIS. A revolutionary new tool to safely screen, stage, and monitor the diabetic foot.
WE HELP YOU KEEP YOUR FEET
VOTIS is a revolutionary new tool to safely screen, stage, and monitor the diabetic foot.
VOTIS provides a clinical decision support for diagnosis and monitoring of diabetic foot syndrome and related conditions.
VOTIS is designed for safe and repeated use over time, and for acute use during surgical procedures.
VOTIS provides objective, repeatable, and measurable data useful to the doctor — regardless of treatment options being used.
VOTIS is non-invasive and ionizing-radiation-free.
Chronic limb-threatening ischemia (CLTI) is an end-stage condition of peripheral artery disease (PAD), which hinders blood flow in the arteries of the leg.
PAD affects more than 200 MILLION PEOPLE worldwide.
CLTI affects 20 MILLION PEOPLE worldwide, 5 MILLION in the US and Europe.
75 THOUSAND non-major amputations (about 2/3 of all amputations) are performed each year in the US.
VOTIS accompanies the PAD/CLTI patient throughout the patient journey.
The patient’s feet are screened for Peripheral Artery Disease.
Most likely, the patient is diabetic and 50 years old or older, or is younger but has had active diabetes for 10 years, or is younger and smokes.
The patient’s specialists assess blood flow, oxygen flow in the foot, severity of ulcers or gangrene, and infection.
The health of the patient’s foot is assessed regularly for clinical decision support as various treatment options are applied.
The doctor performing revascularization, bypass, open surgery, or minor or partial amputation uses the PedFlo™ to assess blood flow in the foot in real time.
For the first time, doctors can properly see what they are doing:
P e d S t a g e ™ shows precise location and severity of disease.
An angiosome is an anatomical unit of tissue fed by a source artery and drained by specific veins.
The foot is divided into multiple angiosomes.
By identifying which areas of the foot lack perfusion, the doctor can identify occluded arteries in the leg.
Portable, inexpensive, easy-to-use
Votis is an inexpensive portable device
Single-use consumable patches affixed to foot encase reusable laser diodes and photodetector sensors that automatically measure scattering and absorption of the light.
Data is automatically converted into 3-digit (0-3) Wound, Ischemia, Foot-Infection (WIFI) Scale score.
To watch the video describing the procedure please contact us
If you have the code
Solid IP position
Protects VOTIS technology and creates competitive barrier to entry.
Seven issued US patents licensed from Columbia University cover hardware, software and cloud-based AI.
License includes proprietary devices and processes developed in the lab and in the field during studies of human subjects.
Viable development plan to bring screening, staging, and intraoperative devices to market.
Merrill Weber, JD
Co-Founder, CEO & President
Previously, president of vascular medical device company sold for >$100 million.
Andreas H. Hielscher, PhD
Co-Founder & Chief Technology Advisor
Professor of Biophotonics, Columbia University.
Brian Glenville, MD
Cardiothoracic surgeon, Jerusalem and London, advisor to start-ups and investors.
David G. Armstrong
DPM, MD, PhD
Leading global expert in amputation prevention and diabetic foot. Professor, USC.
Surgical medical advisor; vascular surgeon and Director, Critical Limb Ischemia Program at Columbia University.
Cisco Systems Expert in Cloud computing, AI and Large Data Transfer Architecture.
SCIENTIFIC ADVISORY BOARD
BOARD OF DIRECTORS
BRIAN GLENVILLE (Executive Chairman)
JERRY KOKOSHKA (Observer)
An article “Diabetic foot ulcer management in a multidisciplinary foot centre: one-year healing, amputation and mortality rate” was published in the Journal of Wound Care.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 876589.
An article “Structured health care for subjects with diabetic foot ulcers results in a reduction of major amputation rates” was published in Cardio Vascular Diabetology.